Fluorescence Detection of MMP-9. I. MMP-9 Selectively Cleaves Lys-Gly-Pro-Arg-Ser-Leu-Ser-Gly-Lys Peptide

Overview

Journal Curr Pharm Biotechnol

Publisher Bentham Science Publishers

Specialties Biotechnology
Pharmacology

Date 2011 Mar 31

PMID 21446907

Citations 4

Authors

Rafal Fudala

Amalendu P Ranjan

Anindita Mukerjee

Jamboor K Vishwanatha

Zygmunt Gryczynski

Julian Borejdo

Pabak Sarkar

Ignacy Gryczynski

Affiliations

Soon will be listed here.

Abstract

MMP-9 enzyme recognizes a peptide sequence Lys-Gly-Pro-Arg-Ser-Leu-Ser-Gly-Lys and cleaves the peptide into two parts. We synthesized a dual fluorophore beacon consisting of 5-FAM and Cy5 dyes. The fluorescence emission of the fluorescein moiety is dramatically quenched by Cy5 molecule due to Förster Resonance Energy Transfer (FRET) and the fluorescence of Cy5 is strongly enhanced. Upon addition of MMP-9 enzyme, the fluorescence of 5-FAM intensifies and Cy5 decreases. The control MMP-2 enzyme does not cause any changes in either 5-FAM or Cy5 fluorescence. We believe that our observation will help in early detection of elevated MMP-9 levels under disease conditions.

Citing Articles

Gelatinase Biosensor Reports Cellular Remodeling During Epileptogenesis.

Bouquier N, Girard B, Arias J, Fagni L, Bertaso F, Perroy J Front Synaptic Neurosci. 2020; 12:15.

PMID: 32372941 PMC: 7186352. DOI: 10.3389/fnsyn.2020.00015.

Design, Synthesis, and Evaluation of a Neurokinin-1 Receptor-Targeted Near-IR Dye for Fluorescence-Guided Surgery of Neuroendocrine Cancers.

Kanduluru A, Srinivasarao M, Low P Bioconjug Chem. 2016; 27(9):2157-65.

PMID: 27529726 PMC: 5343518. DOI: 10.1021/acs.bioconjchem.6b00374.

Matrix metalloproteinase-9 involvement in the structural plasticity of dendritic spines.

Stawarski M, Stefaniuk M, Wlodarczyk J Front Neuroanat. 2014; 8:68.

PMID: 25071472 PMC: 4091410. DOI: 10.3389/fnana.2014.00068.

Micropatterned sensing hydrogels integrated with reconfigurable microfluidics for detecting protease release from cells.

Son K, Shin D, Kwa T, Gao Y, Revzin A Anal Chem. 2013; 85(24):11893-901.

PMID: 24255999 PMC: 4370905. DOI: 10.1021/ac402660z.

References

Williamson R, Marston F, Angal S, Koklitis P, Panico M, Morris H . Disulphide bond assignment in human tissue inhibitor of metalloproteinases (TIMP). Biochem J. 1990; 268(2):267-74. PMC: 1131427. DOI: 10.1042/bj2680267. View

Tan W, Wang K, Drake T . Molecular beacons. Curr Opin Chem Biol. 2004; 8(5):547-53. DOI: 10.1016/j.cbpa.2004.08.010. View

Kridel S, Chen E, Kotra L, Howard E, Mobashery S, Smith J . Substrate hydrolysis by matrix metalloproteinase-9. J Biol Chem. 2001; 276(23):20572-8. DOI: 10.1074/jbc.M100900200. View

Shapiro S . Matrix metalloproteinase degradation of extracellular matrix: biological consequences. Curr Opin Cell Biol. 1998; 10(5):602-8. DOI: 10.1016/s0955-0674(98)80035-5. View

Liu Z, Zhou X, Shapiro S, Shipley J, Twining S, Diaz L . The serpin alpha1-proteinase inhibitor is a critical substrate for gelatinase B/MMP-9 in vivo. Cell. 2000; 102(5):647-55. DOI: 10.1016/s0092-8674(00)00087-8. View

Orpana A . Fluorescence resonance energy transfer (FRET) using ssDNA binding fluorescent dye. Biomol Eng. 2004; 21(2):45-50. DOI: 10.1016/j.bioeng.2003.09.001. View

Lochter A, Sternlicht M, Werb Z, Bissell M . The significance of matrix metalloproteinases during early stages of tumor progression. Ann N Y Acad Sci. 1999; 857:180-93. DOI: 10.1111/j.1749-6632.1998.tb10116.x. View

Bode W, Tschesche H, Grams F, Nagase H, Maskos K . Structural properties of matrix metalloproteinases. Cell Mol Life Sci. 1999; 55(4):639-52. PMC: 11146962. DOI: 10.1007/s000180050320. View

Nagase H, Woessner Jr J . Matrix metalloproteinases. J Biol Chem. 1999; 274(31):21491-4. DOI: 10.1074/jbc.274.31.21491. View

10.

Westermarck J, Kahari V . Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 1999; 13(8):781-92. View

11.

Wu Z, Wu Q, Yang J, Wang H, Ding X, Yang F . Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer. 2008; 122(9):2050-6. DOI: 10.1002/ijc.23337. View

12.

Gohji K, Fujimoto N, Komiyama T, Fujii A, Ohkawa J, Kamidono S . Elevation of serum levels of matrix metalloproteinase-2 and -3 as new predictors of recurrence in patients with urothelial carcinoma. Cancer. 1996; 78(11):2379-87. View

13.

Sternlicht M, Werb Z . How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001; 17:463-516. PMC: 2792593. DOI: 10.1146/annurev.cellbio.17.1.463. View

14.

Stetler-Stevenson W, Krutzsch H, Liotta L . Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J Biol Chem. 1989; 264(29):17374-8. View

15.

Didenko V . DNA probes using fluorescence resonance energy transfer (FRET): designs and applications. Biotechniques. 2001; 31(5):1106-16, 1118, 1120-1. PMC: 1941713. DOI: 10.2144/01315rv02. View

16.

De Clerck Y, Yean T, Ratzkin B, Lu H, Langley K . Purification and characterization of two related but distinct metalloproteinase inhibitors secreted by bovine aortic endothelial cells. J Biol Chem. 1989; 264(29):17445-53. View

17.

Nakajima M, Welch D, Wynn D, Tsuruo T, Nicolson G . Serum and plasma M(r) 92,000 progelatinase levels correlate with spontaneous metastasis of rat 13762NF mammary adenocarcinoma. Cancer Res. 1993; 53(23):5802-7. View

18.

Stocker W, Grams F, Baumann U, Reinemer P, Gomis-Ruth F, McKay D . The metzincins--topological and sequential relations between the astacins, adamalysins, serralysins, and matrixins (collagenases) define a superfamily of zinc-peptidases. Protein Sci. 1995; 4(5):823-40. PMC: 2143131. DOI: 10.1002/pro.5560040502. View

19.

Vasala K, Turpeenniemi-Hujanen T . Serum tissue inhibitor of metalloproteinase-2 (TIMP-2) and matrix metalloproteinase-2 in complex with the inhibitor (MMP-2:TIMP-2) as prognostic markers in bladder cancer. Clin Biochem. 2007; 40(9-10):640-4. DOI: 10.1016/j.clinbiochem.2007.01.021. View

20.

Guan K, Ye H, Yan Z, Wang Y, Hou S . Serum levels of endostatin and matrix metalloproteinase-9 associated with high stage and grade primary transitional cell carcinoma of the bladder. Urology. 2003; 61(4):719-23. DOI: 10.1016/s0090-4295(02)02429-9. View